Pharmacy Value Management
Expert articles and analysis related to pharmacy value management.
AI Summary — Last 24 Hours
Medication affordability and pharmacy benefit design remain the clearest VBC-relevant signal: reports that roughly one-third of patients cannot afford prescribed medications underscore adherence risk for ACOs, Medicare Advantage plans, and Medicaid managed care organizations taking total-cost accountability, especially as high-cost oncology and GLP-1 therapies expand access pressure (Medical Economics, [ASHP GLP practice insights](https://news.google.com/rss/articles/CBMisgFBVV95cUxPSWJXQUFLODBPbHlyYUJ1UU5lSFJwSEVSR1VpcWZocmEzQy0zRy11czVUbTM3TTJWMXVsbkI2YUZGNWhu
Related Articles
Why 1_3 of Patients Can't Afford Their Meds(1)
Why 1_3 of Patients Can't Afford Their Meds(1) Medical Economics
Identifying barriers to prescribing PARP inhibitors, including olaparib, in advanced ovarian cancer.
Identifying barriers to prescribing PARP inhibitors, including olaparib, in advanced ovarian cancer. American Society of Clinical Oncology - ASCO
Bispecific Antibodies, Breast Cancer, and Myeloma: Top OPC Takeaways
Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains
Can Monoclonal Antibodies Change the Course of Multiple System Atrophy?
Can Monoclonal Antibodies Change the Course of Multiple System Atrophy? NEJM Clinician
Impact of glucagon-like peptide-1 receptor agonists on morbidity and mortality in multiple myeloma patients with type 2 diabetes mellitus: A retrospective cohort analysis.
Impact of glucagon-like peptide-1 receptor agonists on morbidity and mortality in multiple myeloma patients with type 2 diabetes mellitus: A retrospective cohort analysis. American Society of Clinica...
World Psychedelics Day: Why Pharmacy Can't Sit This One Out
HRD as a predictor of response to platinum-based chemotherapy and PARP inhibitors in a Chinese ovarian cancer population.
HRD as a predictor of response to platinum-based chemotherapy and PARP inhibitors in a Chinese ovarian cancer population. American Society of Clinical Oncology - ASCO
Turning clinically approved PARP inhibitors into immunotherapy sensitizers by reprogramming the tumor microenvironment in colorectal cancer.
Turning clinically approved PARP inhibitors into immunotherapy sensitizers by reprogramming the tumor microenvironment in colorectal cancer. American Society of Clinical Oncology - ASCO
Synergistic antitumor activity of GLIX1, a small molecule TET2 activator, in combination with PARP inhibition across multiple cancers.
Synergistic antitumor activity of GLIX1, a small molecule TET2 activator, in combination with PARP inhibition across multiple cancers. American Society of Clinical Oncology - ASCO